Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.65 +0.36 (+1.48%)
Official Closing Price Updated: 4:10 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
US Government Shutdown Threatens Deeper Economic Drag, BMO Warns
The United States is grappling with the severe economic fallout of a prolonged government shutdown, now stretching through the entire month of October 2025. With federal operations curtailed and... 
Via MarketMinute
Topics Economy
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
From Pfizer Inc.
Via Business Wire
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
From Pfizer Inc.
Via Business Wire
Why Bio-Techne (TECH) Stock Is Up Today
Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment... 
Via StockStory
Topics Artificial Intelligence Supply Chain World Trade
Which S&P500 stocks are the most active on Friday?
Let's have a look at what is happening on the US markets on Friday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by... 
Via TokenRing AI
Topics Artificial Intelligence Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency
The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing... 
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Why iRhythm (IRTC) Stock Is Trading Up Today
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and... 
Via StockStory
Topics Artificial Intelligence World Trade
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
AbbVie stock dipped early Friday, though the drug giant easily beat views. 
Via Investor's Business Daily
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Edwards Lifesciences Pops As Third-Quarter Beat Lifts 2025 Guidance
Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls. 
Via Investor's Business Daily
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
Thursday's session: most active stock in the S&P500 index
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily
Pfizer Addresses Proposal for Metsera
From Pfizer Inc.
Via Business Wire
Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years
Investing in high-quality stocks with generous dividend payouts can help you gradually build substantial wealth. 
Via The Motley Fool
2 High-Yield Stocks With Fresh Catalysts
Income investors can capture yields above 5% from companies executing business transformations. 
Via The Motley Fool
Topics Lawsuit
S&P 500 Healthcare Sector Navigates Mixed Market Waters on October 29, 2025
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
'I Still Can't Believe It's Around': Cramer Rips Plug Power
Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE) and Dow (DOW) discussed. Plug Power (PLUG) faces concerns over shareholder... 
Via Benzinga
Topics Stocks
1 S&P 500 Stock to Target This Week and 2 We Brush Off
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.